137 related articles for article (PubMed ID: 8262866)
21. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
Consigny S; Bentoucha A; Bonnafous P; Grosset J; Ji B
Antimicrob Agents Chemother; 2000 Oct; 44(10):2919-21. PubMed ID: 10991891
[TBL] [Abstract][Full Text] [Related]
22. Rapid detection of resistance to rifampicin in Mycobacterium leprae.
Roche PW; Shrestha N; Thomas A; Honore N; Cole ST
Lepr Rev; 2000 Dec; 71 Suppl():S96-7; discussion S97-9. PubMed ID: 11201897
[No Abstract] [Full Text] [Related]
23. Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
McDermott-Lancaster RD; Banerjee DK
Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):605-8. PubMed ID: 8151193
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
[TBL] [Abstract][Full Text] [Related]
25. Measurement of hypoxanthine incorporation in purified suspensions of Mycobacterium leprae: a suitable method to screen for anti-leprosy agents in vitro.
Wheeler PR
J Med Microbiol; 1988 Mar; 25(3):167-74. PubMed ID: 3279214
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of phenolic glycolipid-I synthesis in extracellular Mycobacterium leprae as an indicator of antimicrobial activity.
Harris EB; Franzblau SG; Hastings RC
Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):588-91. PubMed ID: 3065422
[TBL] [Abstract][Full Text] [Related]
27. Activity of sparfloxacin against Mycobacterium leprae inoculated into footpads of nude mice.
Gidoh M; Tsutsumi S
Lepr Rev; 1992 Jun; 63(2):108-16. PubMed ID: 1322480
[TBL] [Abstract][Full Text] [Related]
28. Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes.
Michelet C; Avril JL; Arvieux C; Jacquelinet C; Vu N; Cartier F
Antimicrob Agents Chemother; 1997 Jan; 41(1):60-5. PubMed ID: 8980755
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
Dhople AM
Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
[TBL] [Abstract][Full Text] [Related]
30. Ansamycin activity against rifampicin-resistant Mycobacterium leprae.
Hastings RC; Richard VR; Jacobson RR
Lancet; 1984 May; 1(8386):1130. PubMed ID: 6144865
[No Abstract] [Full Text] [Related]
31. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
[TBL] [Abstract][Full Text] [Related]
32. Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system.
Traore I; Ji B; Lienhardt C; Bobin P; Grosset J
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):142-5. PubMed ID: 8690973
[TBL] [Abstract][Full Text] [Related]
33. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
Ji B; Perani EG; Petinon C; Grosset JH
Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):556-61. PubMed ID: 1338596
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans.
Dhople AM; Namba K
J Antimicrob Chemother; 2002 Nov; 50(5):727-9. PubMed ID: 12407131
[TBL] [Abstract][Full Text] [Related]
35. Multidrug resistant Mycobacterium leprae from patients with leprosy.
Maeda S; Matsuoka M; Nakata N; Kai M; Maeda Y; Hashimoto K; Kimura H; Kobayashi K; Kashiwabara Y
Antimicrob Agents Chemother; 2001 Dec; 45(12):3635-9. PubMed ID: 11709358
[TBL] [Abstract][Full Text] [Related]
36. [Novel method for simple detection of mutations conferring drug resistance in Mycobacterium leprae, based on a DNA microarray, and its applicability in developing countries].
Matsuoka M; Suzuki Y; Makino M
Nihon Hansenbyo Gakkai Zasshi; 2010 Sep; 79(3):257-61. PubMed ID: 20857655
[TBL] [Abstract][Full Text] [Related]
37. Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters.
Pascual A; García I; Ramirez de Arellano E; Perea EJ
J Antimicrob Chemother; 1995 Aug; 36(2):425-30. PubMed ID: 8522473
[TBL] [Abstract][Full Text] [Related]
38. Anti-Mycobacterium leprae activity of several quinolones studied in the mouse.
Pattyn SR
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):613-7. PubMed ID: 1666402
[TBL] [Abstract][Full Text] [Related]
39. Limited in vitro multiplication of Mycobacterium leprae: application to screening potential antileprosy compounds.
Dhople AM; Green KJ
Lepr Rev; 1986; 57 Suppl 3():149-62. PubMed ID: 3553808
[No Abstract] [Full Text] [Related]
40. Inhibition of the multiplication of Mycobacterium leprae in nude mice by intermittent administration of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) combined with sparfloxacin.
Gidoh M; Matsuki G; Tsutsumi S; Hidaka T; Nakamura S
Lepr Rev; 1995 Mar; 66(1):39-47. PubMed ID: 7731340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
